Stay updated on Ixazomib Citrate for Relapsed Myeloma Clinical Trial
Sign up to get notified when there's something new on the Ixazomib Citrate for Relapsed Myeloma Clinical Trial page.

Latest updates to the Ixazomib Citrate for Relapsed Myeloma Clinical Trial page
- Check4 days agoChange Detected- Page revision updated from v3.6.2 to v3.6.3, reflecting a newer build of the page. No content changes are indicated by the provided change data.SummaryDifference0.0%

- Check12 days agoChange DetectedAdverse event reporting language was updated to specify CTCAE version 3.0, require reporting the percentage of patients with grade 3+ adverse events by arm, and establish a 2.5-year follow-up window; registry identifiers and the previous post-treatment window were removed from the study record.SummaryDifference0.3%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedNew help and navigation sections have been added to the page, including No longer looking for participants, How to Read a Study Record, Common Questions, How to Join a Study, and an updated Intervention/Treatment label. The revision note has been updated to v3.6.0 and the older Intervention / Treatment label and Revision: v3.5.5 entry were removed.SummaryDifference0.3%

- Check33 days agoChange DetectedThe page revision was updated from v3.5.4 to v3.5.5, indicating a minor update to the page's documentation/versioning rather than substantive content changes.SummaryDifference0.0%

- Check54 days agoChange DetectedThe page's revision label was updated from v3.5.3 to v3.5.4. This is a small metadata update indicating a new build or update to the page, not a substantive change to content.SummaryDifference0.0%

- Check75 days agoChange DetectedThe page’s software/version label has been updated from “Revision: v3.5.0” to “Revision: v3.5.3,” reflecting an interface or release change rather than an update to the clinical trial record.SummaryDifference0.0%

Stay in the know with updates to Ixazomib Citrate for Relapsed Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ixazomib Citrate for Relapsed Myeloma Clinical Trial page.